ATYR ▲ +64.9% - aTyr Pharma, Inc.
$ATYR Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
24-SEP-2026 06:03 AM ET
Share this post
More filings for $ATYR
ATYR - aTyr Pharma, Inc. - SEC Filing Update (07-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 7, 2026ATYR ▲ +5.4% - aTyr Pharma, Inc.Sep 24, 2026ATYR ▼ -9.3% - aTyr Pharma, Inc.Sep 1, 2026ATYR - aTyr Pharma, Inc. - SEC Filing Update (06-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 6, 2026$ATYR SEC Filing Update (27-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 27, 2026$ATYR SEC Filing Update (08-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 8, 2026
View full $ATYR filing history →💬 Comments
Loading comments…
Leave a comment